We systematically compare levels of mutations from the same (KRAS) and different (PIK3CA and FBWX7) genomic loci and miRNAs (namely miR-221, miR-222, and miR-141) in cell extracts and culture supernatants on the one hand, and the corresponding mouse tumor xenografts and matched blood samples from these mice on the other. This evidence concerns the gene KRAS and neoplasm.